Patent details

Basic Information

Publication number:

93067

Type:

SPC

SPC Type:

Medical

Basic Patent Number:

EP048033021

Legal Status:

Active

Application number:

93067

First applicant's nationality:

Procedural language:

French

Marketing Authorization

Marketing Authorization Number:

EU/1/15/1047 - Blincyto - blinatumomab

Marketing Authorization Type:

Marketing Authorization Date:

25/11/2015

Marketing Authorization Status:

Accepted

Marketing Authorization Country:

Dates

Filing date:

11/05/2016

First Marketing Authorization date:

25/11/2015

Grant date:

11/07/2016

Activation date:

26/11/2024

Publication date:

11/07/2016

Lapsed date:

Expiration date:

Renunciation date:

Revocation date:

Annulment date:

Basic SPC Expiration:

26/11/2029

SPC Extension Expiration:

26/11/2029

Rejection date:

Withdrawal date:

Owner

From:

11/05/2016

 

 

Name:

AMGEN RESEARCH (MUNICH) GMBH

Address:

STAFFELSEESTRASSE 2, 81477 MÜNCHEN, Germany (DE)

Agent

Name:

OFFICE FREYLINGER S.A.

From:

11/05/2016

Address:

Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)

To:

Inventor

1

Name:

Baeuerle Patrick

Address:

Germany (DE)

2

Name:

Itin Christian

Address:

Germany (DE)

3

Name:

Hofmeister Robert

Address:

Germany (DE)

4

Name:

Prang Nadja

Address:

Germany (DE)

5

Name:

Wolf Andreas

Address:

Germany (DE)

6

Name:

Hanakam Frank

Address:

Germany (DE)

7

Name:

Urbig Thomas

Address:

Germany (DE)

Publication

Bulletin

Bulletin Heading:

SPC3

Bulletin edition number:

2025/04

Publication date:

04/03/2025

Description:

Section E : Supplementary Protection certificates entered into force – IA publication

Annual Fees

Annual Fee Due Date:

01/12/2025

Annual Fee Number:

22

Annual Fee Amount:

420 Euro

Expected Payer:

Last Annual Fee Payment Date:

22/10/2024

Last Annual Fee Paid Number:

21

Last Annual Fee Paid Amount:

410 Euro

Payer:

ANAQUA SERVICES (ANC. SGA2)

Filing date	Document type	Number of pages